Document is current
Any future updates will be listed below
-
Authors
Bandiwadekar, Chaitra
Naorem, Leimarembi Devi
Moiyadi, Aliasgar V.
Singh, Vikas
Shetty, Prakash
Epari, Sridhar
Tandel, Harshali
Yelukar, Roohi
Poojary, Disha
Raghuram, Gorantla V.
Shabrish, Snehal
Chandrani, Pratik
Mittra, Indraneel
-
Funding
Funding for this research was provided by:
Department of Atomic Energy, Government of India (CTCTMC)
- License Information
-
More Information
Article History
Received: 10 June 2025
Revised: 14 August 2025
Accepted: 23 August 2025
First Online: 30 September 2025
Competing interests
: The authors declare no competing interests.
: The present study is part of a larger prospective study to evaluate the effect of R-Cu on survival in glioblastoma patients. The overall study was approved by Institutional Ethics Committee (IEC) of Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Tata Memorial Centre (TMC) (Approval no. 3456). All R-Cu treated participants signed a written informed consent forms which were approved by the IEC. Control samples were obtained from the tumour tissue repository with waiver of consent. The present study is a comparative analysis of ten R-Cu treated and ten R-Cu untreated (control) patient samples obtained at surgery. All experiments were performed in accordance with the relevant guidelines and regulations stipulated by IEC.
